galeterone
Phase 3- Indications
- Prostate cancer, Pancreatic cancer
Company intelligence / Profile preview
LTN Pharmaceuticals, Inc.
Elkridge, Maryland, United Statesumaryland.edu ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
LTN Pharmaceuticals was involved in a Phase 3 clinical trial for galeterone in metastatic castration-resistant prostate cancer, which was terminated. The company also had a program for Myc-102 targeting onychomycosis, which is pending.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on LTN Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTN Pharmaceuticals, Inc..